Biopharmaceutical royalties buyer Royalty Pharma plc (Nasdaq:RPRX) said on Wednesday that it has entered into an agreement with biotechnology company Biogen Inc (Nasdaq:BIIB) to provide up to USD250m in research and development funding for litifilimab, a first-in-class biologic in Phase 3 trials for systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).
Litifilimab has demonstrated proof-of-concept and a well-tolerated safety profile in both conditions, with results published in the New England Journal of Medicine. It has the potential to be the first targeted biologic approved for CLE, a disease with no currently available treatments.
Biogen expects Phase 3 trial results between 2026 and 2027.
Under the deal, Royalty Pharma will provide funding over six quarters in exchange for regulatory milestones and mid-single-digit royalties on global sales.
HUTCHMED doses first patient in global trial of ATTC candidate HMPL-A580
Ensorcell adds new senior leadership team members
Sino Biological launches 2026-2027 Northern Hemisphere influenza vaccine strain antigens
Sanaregen receives FDA clearance for retinal degeneration clinical trial
Lynk Pharmaceuticals reveals positive topline results from zemprocitinib Phase III clinical trial
ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117
Ono Pharmaceutical expands multi-target research collaboration with Congruence Therapeutics
United Therapeutics' ralinepag reduces risk of clinical worsening in pivotal PAH study
Genentech's fenebrutinib meets primary endpoint in pivotal Phase III study for multiple sclerosis
ValiRx establishes animal health subsidiary to target veterinary oncology market